Michelle Kwok
Psychiatry · San Mateo, CANPI 1104905959
Payments from drug & device makers
Across 252 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Axsome Therapeutics, Inc.$839
- Lundbeck LLC$603
- Takeda Pharmaceuticals U.S.A., Inc.$574
- Vanda Pharmaceuticals Inc.$247
- plus $474 from 6 others
What the payments were for
- Food & beverage$5,34898%
- Education$1182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $1,458 |
| AbbVie | 83 | $1,270 |
| Axsome Therapeutics, Inc. | 28 | $839 |
| Lundbeck LLC | 22 | $603 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $574 |
| Vanda Pharmaceuticals Inc. | 9 | $247 |
| Otsuka America Pharmaceutical, Inc. | 7 | $181 |
| Sunovion Pharmaceuticals Inc. | 18 | $127 |
| Alkermes, Inc. | 2 | $47 |
| Johnson & Johnson | 1 | $45 |
| Shire North American Group Inc | 2 | $40 |
| Neurocrine Biosciences, Inc. | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$129
How this compares
$5,466 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $21,941 |
| Duloxetine Hcl | 76 | $2,553 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $2,275 |
| Aripiprazole | 30 | $2,061 |
| Paliperidone ErPaliperidone | 13 | $1,848 |
| Bupropion XlBupropion Hcl | 52 | $1,350 |
| Gabapentin | 77 | $1,319 |
| Quetiapine Fumarate | 50 | $1,064 |
| Sertraline Hcl | 48 | $1,038 |
| Fluvoxamine Maleate | 16 | $1,022 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $990 |
| Trazodone Hcl | 42 | $903 |
| Vilazodone Hcl | 17 | $746 |
| Lamotrigine | 30 | $540 |
| Olanzapine | 22 | $534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $45 | $21,94113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Mateo
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.